Conference Highlights ASCO

Skip to main content

Conference Highlights ASCO

Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer

Conference Highlights ASCO

Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions

Conference Highlights ASCO

PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer

Disparities in Cancer Care, Conference Highlights ASCO

ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care

Wayne Kuznar

Conference Highlights ASCO, Lung Cancer

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Value-Based Care, Conference Highlights ASCO

Rapid Biosimilar Adoption Possible in Community Oncology Practice

Chase Doyle

Multiple Myeloma, Conference Highlights ASCO

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

1
2

Page 1 of 2
Results 1 - 10 of 18